The DOI matches its Crossref record; 158 of the 158 references it cites were found in a registry or an index.
Fructose and sugar: A major mediator of non-alcoholic fatty liver disease
Open accessAbstract
Nonalcoholic Fatty Liver Disease (NAFLD) is the hepatic manifestation of metabolic syndrome, and its rising prevalence parallels the rise in obesity and diabetes. Historically thought to result from overnutrition and sedentary lifestyle, recent evidence suggests that diets high in sugar (from sucrose and/or high fructose corn syrup (HFCS)) not only increases the risk for NAFLD, but also, nonalcoholic steatohepatitis (NASH). Here we review the experimental and clinical evidence that fructose precipitates fat accumulation in the liver, due to both increased lipogenesis and impaired fat oxidation. Recent evidence suggests that the predisposition to fatty liver is linked with metabolism of fructose by fructokinase C, resulting in ATP consumption, nucleotide turnover and uric acid generation that mediate fat accumulation. Alterations in gut permeability, microbiome, and associated endotoxemia contributes to the risk of NAFLD and NASH. Early clinical studies suggest that reducing sugary beverages and total fructose intake, especially from added sugars, may have a significant benefit on reducing hepatic fat accumulation. We suggest larger, more definitive trials to determine if lowering sugar/HFCS intake, and/or blocking uric acid generation, may help reduce NAFLD and its downstream complications of cirrhosis and chronic liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sontrop, J. M., Dixon, S. N., Garg, A. X., Buendia-Jimenez, I., Dohein, O., Huang, S.-H. S., & Clark, W. F. (2013) · American Journal of Nephrology · doi:10.1159/000350377 · Cited by 5,871
Overweight and obesity in the United States: prevalence and trends, 1960–1994
Flegal, K., Carroll, M., Kuczmarski, R., & Johnson, C. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800541 · Cited by 3,045
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Stanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37385 · Cited by 1,765
Anderson, E. J., Lustig, M. E., Boyle, K. E., Woodlief, T. L., Kane, D. A., Lin, C.-T., Price, J. W., Kang, L., Rabinovitch, P. S., Szeto, H. H., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37048 · Cited by 1,253 · cited 1×
“One potential explanation is that, like fructose, high-fat diets induce mitochondrial oxidative stress.(133) Nevertheless, mice lacking fructokinase show marked protection from fatty liver and insulin resistance, highlighting the key role of fructose in western diet-induced NAFLD.”
A causal role for uric acid in fructose-induced metabolic syndrome
Nakagawa, T., Hu, H., Zharikov, S., Tuttle, K. R., Short, R. A., Glushakova, O., Ouyang, X., Feig, D. I., Block, E. R., Herrera-Acosta, J., et al. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00140.2005 · Cited by 1,104
Self-citationFructose consumption as a risk factor for non-alcoholic fatty liver disease
Ouyang, X., Cirillo, P., Sautin, Y., McCall, S., Bruchette, J. L., Diehl, A. M., Johnson, R. J., & Abdelmalek, M. F. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.02.011 · Cited by 863
Self-citationKanellis, J., Watanabe, S., Li, J. H., Kang, D. H., Li, P., Nakagawa, T., Wamsley, A., Sheikh-Hamad, D., Lan, H. Y., Feng, L., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000072820.07472.3b · Cited by 786
Self-citationThe role of fructose in the pathogenesis of NAFLD and the metabolic syndrome
Lim, J. S., Mietus-Snyder, M., Valente, A., Schwarz, J.-M., & Lustig, R. H. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.41 · Cited by 771
Cited by
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationFrom NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
Metabolomics for Investigating Physiological and Pathophysiological Processes
Wishart, D. S. (2019) · Physiological Reviews · doi:10.1152/physrev.00035.2018 · Cited by 1,212
The role of sugar-sweetened beverages in the global epidemics of obesity and chronic diseases
Malik, V. S., & Hu, F. B. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00627-6 · Cited by 854
Metabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2022) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 770
Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate
Zhao, S., Jang, C., Liu, J., Uehara, K., Gilbert, M., Izzo, L., Zeng, X., Trefely, S., Fernandez, S., Carrer, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2101-7 · Cited by 553
Bile Acids as Metabolic Regulators and Nutrient Sensors
Chiang, J. Y. L., & Ferrell, J. M. (2019) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082018-124344 · Cited by 437
How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
Geng, Y., Faber, K. N., de Meijer, V. E., Blokzijl, H., & Moshage, H. (2021) · Hepatology International · doi:10.1007/s12072-020-10121-2 · Cited by 432
García-Montero, C., Fraile-Martínez, O., Gómez-Lahoz, A. M., Pekarek, L., Castellanos, A. J., Noguerales-Fraguas, F., Coca, S., Guijarro, L. G., García-Honduvilla, N., Asúnsolo, A., et al. (2021) · Nutrients · doi:10.3390/nu13020699 · Cited by 431
Guo, X., Yin, X., Liu, Z., & Wang, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415489 · Cited by 412
The links between gut microbiota and obesity and obesity related diseases
Geng, J., Ni, Q., Sun, W., Li, L., & Feng, X. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112678 · Cited by 399
High-fructose corn syrup enhances intestinal tumor growth in mice
Goncalves, M. D., Lu, C., Tutnauer, J., Hartman, T. E., Hwang, S.-K., Murphy, C. J., Pauli, C., Morris, R., Taylor, S., Bosch, K., et al. (2019) · Science · doi:10.1126/science.aat8515 · Cited by 374
Cusi, K., Abdelmalek, M. F., Apovian, C. M., Balapattabi, K., Bannuru, R. R., Barb, D., Bardsley, J. K., Beverly, E. A., Corbin, K. D., ElSayed, N. A., et al. (2025) · Diabetes Care · doi:10.2337/dci24-0094 · Cited by 332
Self-citationAsymptomatic hyperuricaemia: a silent activator of the innate immune system
Joosten, L. A. B., Crişan, T. O., Bjornstad, P., & Johnson, R. J. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0334-3 · Cited by 319
Self-citationCurrent treatment paradigms and emerging therapies for NAFLD/NASH
Raza, S. (2021) · Frontiers in Bioscience · doi:10.2741/4892 · Cited by 310
The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state
Hodson, L., & Gunn, P. J. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0256-9 · Cited by 309
Dietary Fructose and the Metabolic Syndrome
Taskinen, M.-R., Packard, C. J., & Borén, J. (2019) · Nutrients · doi:10.3390/nu11091987 · Cited by 295
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
Molecular aspects of fructose metabolism and metabolic disease
Herman, M. A., & Birnbaum, M. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.09.010 · Cited by 290
Discovery of farnesoid X receptor and its role in bile acid metabolism
Chiang, J. Y. L., & Ferrell, J. M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111618 · Cited by 288
Uric acid in metabolic syndrome: Does uric acid have a definitive role?
Copur, S., Demiray, A., & Kanbay, M. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.04.022 · Cited by 287
Association Between Soft Drink Consumption and Mortality in 10 European Countries
Mullee, A., Romaguera, D., Pearson-Stuttard, J., Viallon, V., Stepien, M., Freisling, H., Fagherazzi, G., Mancini, F. R., Boutron-Ruault, M.-C., Kühn, T., et al. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.2478 · Cited by 269
Non-alcoholic fatty liver disease: A patient guideline
Francque, S. M., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, J. V., Zelber-Sagi, S., Hallsworth, K., Busetto, L., Frühbeck, G., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100322 · Cited by 264
The Toxic Impact of Honey Adulteration: A Review
Fakhlaei, R., Selamat, J., Khatib, A., Razis, A. F. A., Sukor, R., Ahmad, S., & Babadi, A. A. (2020) · Foods · doi:10.3390/foods9111538 · Cited by 262
Geidl-Flueck, B., Hochuli, M., Németh, Á., Eberl, A., Derron, N., Köfeler, H. C., Tappy, L., Berneis, K., Spinas, G. A., & Gerber, P. A. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.027 · Cited by 238
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Haas, J. T., Vonghia, L., Mogilenko, D. A., Verrijken, A., Molendi-Coste, O., Fleury, S., Deprince, A., Nikitin, A., Woitrain, E., Ducrocq-Geoffroy, L., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0076-1 · Cited by 155
Breakthroughs in therapies for NASH and remaining challenges
Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132
Zhang, S., Gan, S., Zhang, Q., Liu, L., Meng, G., Yao, Z., Wu, H., Gu, Y., Wang, Y., Zhang, T., et al. (2022) · International Journal of Epidemiology · doi:10.1093/ije/dyab174 · Cited by 113
Saponaro, C., Sabatini, S., Gaggini, M., Carli, F., Rosso, C., Positano, V., Armandi, A., Caviglia, G. P., Faletti, R., Bugianesi, E., et al. (2022) · Liver International · doi:10.1111/liv.15377 · Cited by 116
Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH
Kang, G. G., Trevaskis, N. L., Murphy, A. J., & Febbraio, M. A. (2023) · iScience · doi:10.1016/j.isci.2022.105905 · Cited by 94
“Consumption of SSBs and HFD drives the development of obesity, a major risk factor for NAFLD in developed countries.(15,16) The link between obesity and NAFLD/NASH has been appreciated in bariatric surgery studies where NAFLD was detected in 85%–95% of patients with obesity,(17) aligning with a meta-analysis report in…”
BackgroundSimons, N., Veeraiah, P., Simons, P. I., Schaper, N. C., Kooi, M. E., Schrauwen-Hinderling, V. B., Feskens, E. J., van der Ploeg, E. (., Van den Eynde, M. D., Schalkwijk, C. G., et al. (2021) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa332 · Cited by 74
Henney, A. E., Gillespie, C. S., Alam, U., Hydes, T. J., & Cuthbertson, D. J. (2023) · Nutrients · doi:10.3390/nu15102266 · Cited by 74
Zhang, S., Gu, Y., Bian, S., Lu, Z., Zhang, Q., Liu, L., Meng, G., Yao, Z., Wu, H., Wang, Y., et al. (2021) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa380 · Cited by 70
Bilal, M., Ashraf, S., & Zhao, X. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.931458 · Cited by 58
MASLD treatment—a shift in the paradigm is imminent
Machado, M. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1316284 · Cited by 51
Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis
Morikawa, R., Nakamoto, N., Amiya, T., Chu, P.-S., Koda, Y., Teratani, T., Suzuki, T., Kurebayashi, Y., Ueno, A., Taniki, N., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.033 · Cited by 40
Liu, Z., Huang, H., Zeng, Y., Chen, Y., & Xu, C. (2023) · British Journal Of Nutrition · doi:10.1017/s0007114522003956 · Cited by 32
“Among them, fructose is a key macronutrient for the development of NAFLD and IR (33,34) , which not only disrupts de novo lipogenesis and fat oxidation (35) but also causes intestinal barrier deterioration (36) .”
Authors, & Collaborators: (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2388 · Cited by 30
Pan, C., Liu, J., Gao, Y., Yang, M., Hu, H., Liu, C., Qian, M., Yuan, H.-Y., Yang, S., Zheng, M.-H., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.018 · Cited by 27
Amorim, R., Simões, I., Veloso, C., Carvalho, A., Simões, R., Pereira, F., Thiel, T., Normann, A., Morais, C., Jurado, A., et al. (2021) · Nutrients · doi:10.3390/nu13051723 · Cited by 21
“Fructose overload can lead to a large, rapid increase in the hexose-and triose-phosphate pools, potentially increasing substrate delivery for central carbon metabolic pathways increasing the risk for the development and progression of NAFLD [43,44].”
BackgroundInfluentialLiver abnormalities in Turner syndrome: the importance of estrogen replacement
Fedor, I., Zold, E., & Barta, Z. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac124 · Cited by 16
“Apart from alcoholic beverages, excessive fructose and sugar consumption can aggravate hepatic enzyme abnormalities and liver steatosis [55-57].”
Background
Metadata
- Authors
- Jensen, T., Abdelmalek, M. F., Sullivan, S., Nadeau, K. J., Green, M., Roncal, C., Nakagawa, T., Kuwabara, M., Sato, Y., Kang, D.-H., Tolan, D. R., Sanchez-Lozada, L. G., Rosen, H. R., Lanaspa, M. A., Diehl, A. M., & Johnson, R. J.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 68
- Issue
- 5
- Pages
- 1063-1075
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2788821298
- Cited by
- 941
- References
- 158
- FWCI
- 57.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.